Preclinical evaluation of s18886 in an experimental model of coronary arterial thrombosis

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 5, 2006, Pages 239-248

  Hong, Ting Ting ^a   Huang, Jinbao ^a   Driscoll, Edward ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Arterial thrombosis; Clopidogrel; Platelets; S18886; Thromboxane receptor antagonist

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [6 [[(4 CHLOROPHENYL)SULFONYL]AMINO] 2 METHYL 5,6,7,8 TETRAHYDRO 1 NAPHTHALENYL]PROPANOIC ACID SODIUM; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; PLACEBO; S 18886; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY THROMBOSIS; CORONARY BLOOD VESSEL; DOG; DRUG SCREENING; EX VIVO STUDY; EXPERIMENTAL MODEL; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; TONGUE;

ANIMALS; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; NAPHTHALENES; PLATELET AGGREGATION; PROPIONIC ACIDS; RECEPTORS, THROMBOXANE;

EID: 33751162130     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000248234.08277.7e     Document Type: Article

References (32)

1. Simonet S, Descombes JJ, Vallez MO, et al. S18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S18204 in all species, except in the guinea-pig. Adv Exp Med Biol. 1997;433:173-176.
2. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation. 1993;87:1563-1569.
3. Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol. 1996;42:782-785.
4. Cimetiere B, Dubuffet T, Muller O, et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett. 1998;8:1375-1380.
5. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724-1728.
6. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-342.
7. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J. 2005;26:1557-1561.
8. Worth NF, Berry CL, Thomas AC, et al. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis. 2005;183:65-73.
9. Zuccollo A, Shi C, Mastroianni R, et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation. 2005;112:3001-3008.
10. Belhassen L, Pelle G, Dubois-Rande JL, et al. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003;41:1198-1204.
11. Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. J Cardiovasc Pharmacol. 2005;45:389-395.
12. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res. 1980;17:841-853.
13. Gralinski MR, Driscoll EM, Friedrichs GS, et al. Reduction of Myocardial Necrosis After Glycosaminoglycan Administration: Effects of a Single Intravenous Administration of Heparin or N-Acetylheparin 2 Hours Before Regional Ischemia and Reperfusion. J Cardiovasc Pharmacol Ther. 1996;1:219-228.
14. Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685-691.
15. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
16. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994-2998.
17. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30:293-331.
18. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167:2831-2838.
19. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.
20. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res. 2001;89:650-660.
21. Yang D, Feletou M, Levens N, et al. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension. 2003;41:143-148.
22. Yang D, Feletou M, Boulanger CM, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol. 2002;136:104-110.
23. Ge T, Hughes H, Junquero DC, et al. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res. 1995;76:1003-1010.
24. Hock CE, Brezinski ME, Lefer AM. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia. Eur J Pharmacol. 1986;122:213-219.
25. Rolin S, Petein M, Tchana-Sato V, et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther. 2003;306:59-65.
26. Hong TT, Huang J, Driscoll E, et al. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol. 2005;46:526-533.
27. Bonow RO, Lipson LC, Sheehan FH, et al. Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol. 1981;47:258-264.
28. Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol. 1997;32:437-502.
29. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001;12:443-447.
30. Mickelson JK, Hoff PT, Homeister JW, et al. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol. 1993;21:502-510.
31. Madan M, Blankenship JC, Berkowitz SD. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Curr Opin Hematol. 1999;6:334-341.
32. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.